| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Alternative Names | CDC37, Hsp90 co-chaperone Cdc37, Cell division control protein 37, Hsp90 chaperone protein kinase-targeting subunit, CDC37_HUMAN, CDC37A, p50, p50Cdc37, S. cerevisiae hypothetical protein CDC37 |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | Native human Cdc37, full length |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
CDC37 is a co-chaperone of HSP90 that plays a pivotal role in stabilizing and directing HSP90 to a wide array of protein kinases, including CDK4, CDK6, SRC, RAF1, and eIF2α kinases. By facilitating the maturation and functional maintenance of these kinases, CDC37 is essential for signal transduction, cell cycle progression, and stress responses.
In the nervous system, CDC37’s regulation of kinase stability intersects with pathways critical for neuronal survival, synaptic plasticity, and neuroinflammation. Dysregulation of CDC37 or its client kinases has been implicated in neurodegenerative conditions such as Alzheimer’s disease and Parkinson’s disease, where aberrant kinase signaling contributes to tau hyperphosphorylation, protein aggregation, and neuronal loss.
Given its central role in proteostasis and kinase regulation, CDC37 is emerging as a potential therapeutic target for modulating neurodegenerative signaling cascades.
A 1:2000 dilution of SPC-142 was sufficient for detection of cdc37 in 20 µg of HeLa cell lysate by ECL immunoblot analysis.
Cite this product varies by variant:
- SPC-142D — Size: 100 ug: CDC37 Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-142D, RRID: AB_11232608)
- SPC-142D-A390 — Size: 100 ug: CDC37 Antibody: ATTO 390 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-142D-A390, RRID: AB_2703535)
- SPC-142D-A488 — Size: 100 ug: CDC37 Antibody: ATTO 488 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-142D-A488, RRID: AB_2703536)
- SPC-142D-A594 — Size: 100 ug: CDC37 Antibody: ATTO 594 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-142D-A594, RRID: AB_2703538)
- SPC-142D-APC — Size: 100 ug: CDC37 Antibody: APC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-142D-APC, RRID: AB_2703544)
- SPC-142D-BI — Size: 100 ug: CDC37 Antibody: Biotin (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-142D-BI, RRID: AB_2703545)
- SPC-142D-FITC — Size: 100 ug: CDC37 Antibody: FITC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-142D-FITC, RRID: AB_2703546)
- SPC-142D-HRP — Size: 100 ug: CDC37 Antibody: HRP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-142D-HRP, RRID: AB_2703547)
- SPC-142D-PCP — Size: 100 ug: CDC37 Antibody: PerCP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-142D-PCP, RRID: AB_2703549)
- SPC-142D-RPE — Size: 100 ug: CDC37 Antibody: RPE (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-142D-RPE, RRID: AB_2703550)
- SPC-142S — Size: 12 ug: CDC37 Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SPC-142S, RRID: AB_11232608)
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
2. Stepanova L, Leng X., Parker S.B., Harper J.W. (1996) Genes Dev. 10(12): 1491-1502.
3. Kimura Y., et al. (1997) Genes Dev. 11(14): 1775-1185.
4. Gray P.J., et al. (2008) Nat Rev Cancer. 8(7): 491-495.